CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Mesenchymal stem cells can develop into osteoblasts, making them a promising cell-based osteoporosis treatment. Despite their therapeutic potential, their molecular processes are little known. Bioinformatics and experimental analysis were used to determine the molecular processes of bone marrow mesenchymal stem cell (BMSC) therapy for postmenopausal osteoporosis (PMO).

Material and methods:
We used weighted gene co-expression network analysis (WGCNA) to isolate core gene sets from two GEO microarray datasets (GSE7158 and GSE56815). GeneCards found PMO-related genes. GO, KEGG, Lasso regression, and ROC curve analysis refined our candidate genes. Using the GSE105145 dataset, we evaluated KLF2 expression in BMSCs and examined the link between KLF2 and PIK3CA using Pearson correlation analysis. We created a protein-protein interaction network of essential genes involved in osteoblast differentiation and validated the functional roles of KLF2 and PIK3CA in BMSC osteoblast differentiation in vitro.

Results:
We created 6 co-expression modules from 10 419 differentially expressed genes (DEGs). PIK3CA, the key gene in the PI3K-Akt pathway, was among 197 PMO-associated DEGs. KLF2 also induced PIK3CA transcription in PMO. BMSCs also expressed elevated KLF2. BMSC osteoblast differentiation involved the PI3K-Akt pathway. In vitro, KLF2 increased PIK3CA transcription and activated the PI3K-Akt pathway to differentiate BMSCs into osteoblasts.

Conclusions:
BMSCs release KLF2, which stimulates the PIK3CA-dependent PI3K-Akt pathway to treat PMO. Our findings illuminates the involvement of KLF2 and the PI3K-Akt pathway in BMSC osteoblast development, which may lead to better PMO treatments.

 
REFERENCES (42)
1.
Shevroja E, Cafarelli FP, Guglielmi G, Hans D. DXA parameters, trabecular bone score (TBS) and bone mineral density (BMD), in fracture risk prediction in endocrine-mediated secondary osteoporosis. Endocrine 2021; 74: 20-8.
 
2.
Shi H, Jiang X, Xu C, Cheng Q. MicroRNAs in serum exosomes as circulating biomarkers for postmenopausal osteoporosis. Front Endocrinol (Lausanne) 2022; 13: 819056.
 
3.
Migliorini F, Maffulli N, Colarossi G, Eschweiler J, Tingart M, Betsch M. Effect of drugs on bone mineral density in postmenopausal osteoporosis: a Bayesian network meta-analysis. J Orthop Surg Res 2021; 16: 533.
 
4.
Migliorini F, Giorgino R, Hildebrand F, et al. Fragility fractures: risk factors and management in the elderly. Medicina (Kaunas) 2021; 57: 1119.
 
5.
Postmenopausal osteoporosis. N Engl J Med 2016; 374: 1797.
 
6.
Bijelic R, Milicevic S, Balaban J. Risk factors for osteoporosis in postmenopausal women. Med Arch 2017; 71: 25-8.
 
7.
Migliorini F, Maffulli N, Spiezia F, Peretti GM, Tingart M, Giorgino R. Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res 2021; 16: 351.
 
8.
Migliorini F, Colarossi G, Baroncini A, Eschweiler J, Tingart M, Maffulli N. Pharmacological management of postmenopausal osteoporosis: a level i evidence based - expert opinion. Expert Rev Clin Pharmacol 2021; 14: 105-19.
 
9.
Deng YX, He WG, Cai HJ, et al. Analysis and validation of hub genes in blood monocytes of postmenopausal osteoporosis patients. Front Endocrinol (Lausanne) 2021; 12: 815245.
 
10.
Noronha-Matos JB, Correia-de-Sa P. Mesenchymal stem cells ageing: targeting the “purinome” to promote osteogenic differentiation and bone repair. J Cell Physiol 2016; 231: 1852-61.
 
11.
Chen W, Chen X, Chen AC, et al. Melatonin restores the osteoporosis-impaired osteogenic potential of bone marrow mesenchymal stem cells by preserving SIRT1-mediated intracellular antioxidant properties. Free Radic Biol Med 2020; 146: 92-106.
 
12.
Luo ZW, Li FX, Liu YW, et al. Aptamer-functionalized exosomes from bone marrow stromal cells target bone to promote bone regeneration. Nanoscale 2019; 11: 20884-92.
 
13.
Migliorini F, Maffulli N, Spiezia F, Tingart M, Maria PG, Riccardo G. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res 2021; 16: 318.
 
14.
Lai K, Killingsworth MC, Lee CS. Gene of the month: PIK3CA. J Clin Pathol 2015; 68: 253-7.
 
15.
Liu B, Wang A, Cao Z, Li J, Zheng M, Xu Y. Mechanism of pilose antler in treatment of osteoporosis based on network pharmacology. J Healthc Eng 2022; 2022: 5298892.
 
16.
Hu J, Mao Z, He S, et al. Icariin protects against glucocorticoid induced osteoporosis, increases the expression of the bone enhancer DEC1 and modulates the PI3K/Akt/GSK3beta/beta-catenin integrated signaling pathway. Biochem Pharmacol 2017; 136: 109-21.
 
17.
Jha P, Das H. KLF2 in regulation of NF-kappaB-mediated immune cell function and inflammation. Int J Mol Sci 2017; 18: 2383.
 
18.
Li Y, Wang J, Ma Y, et al. MicroRNA-15b shuttled by bone marrow mesenchymal stem cell-derived extracellular vesicles binds to WWP1 and promotes osteogenic differentiation. Arthritis Res Ther 2020; 22: 269.
 
19.
Kim I, Kim JH, Kim K, Seong S, Kim N. The IRF2BP2-KLF2 axis regulates osteoclast and osteoblast differentiation. BMB Rep 2019; 52: 469-74.
 
20.
Ebert R, Meissner-Weigl J, Zeck S, et al. Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells. Mol Cancer 2014; 13: 265.
 
21.
Sako K, Fukuhara S, Minami T, et al. Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2. J Biol Chem 2009; 284: 5592-601.
 
22.
Huang X, Hao S, Liu J, et al. The ubiquitin ligase Peli1 inhibits ICOS and thereby Tfh-mediated immunity. Cell Mol Immunol 2021; 18: 969-78.
 
23.
Malakoti F, Zare F, Zarezadeh R, et al. The role of melatonin in bone regeneration: a review of involved signaling pathways. Biochimie 2022; 202: 56-70.
 
24.
Zhao F, Xu Y, Ouyang Y, et al. Silencing of miR-483-5p alleviates postmenopausal osteoporosis by targeting SATB2 and PI3K/AKT pathway. Aging (Albany NY) 2021; 13: 6945-56.
 
25.
Gong L, Tang Y, An R, Lin M, Chen L, Du J. RTN1-C mediates cerebral ischemia/reperfusion injury via ER stress and mitochondria-associated apoptosis pathways. Cell Death Dis 2017; 8: e3080.
 
26.
He X, Chai P, Li F, et al. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3. Mol Cancer 2020; 19: 115.
 
27.
Zhang Y, Cao X, Li P, et al. PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model. J Cell Physiol 2020; 235: 5511-24.
 
28.
Kou J, Zheng X, Guo J, Liu Y, Liu X. MicroRNA-218-5p relieves postmenopausal osteoporosis through promoting the osteoblast differentiation of bone marrow mesenchymal stem cells. J Cell Biochem 2020; 121: 1216-26.
 
29.
Zhou Y, Liu C, He J, et al. KLF2(+) stemness maintains human mesenchymal stem cells in bone regeneration. Stem Cells 2020; 38: 395-409.
 
30.
Xu R, Shen X, Xie H, et al. Identification of the canonical and noncanonical role of miR-143/145 in estrogen-deficient bone loss. Theranostics 2021; 11: 5491-510.
 
31.
Yuan X, Wu Y, Yang K, Liu H, Zhang G. Exploring the effect of Jiawei Buguzhi Pills on TGF-beta-Smad pathway in postmenopausal osteoporosis based on integrated pharmacological strategy. Evid Based Complement Alternat Med 2021; 2021: 5556653.
 
32.
Cui H, Han G, Sun B, et al. Activating PIK3CA mutation promotes osteogenesis of bone marrow mesenchymal stem cells in macrodactyly. Cell Death Dis 2020; 11: 505.
 
33.
Wang H, Zhou Y, Yu D, Zhu H. Klf2 contributes to the stemness and self-renewal of human bone marrow stromal cells. Cytotechnology 2016; 68: 839-48.
 
34.
Zhou Y, Yu D, Zhu H. Optimization of culture condition of human bone marrow stromal cells in terms of purification, proliferation, and pluripotency. In Vitro Cell Dev Biol Anim 2014; 50: 822-30.
 
35.
Luo H, Huang F, Huang Z, et al. microRNA-93 packaged in extracellular vesicles from mesenchymal stem cells reduce neonatal hypoxic-ischemic brain injury. Brain Res 2022; 1794: 148042.
 
36.
Xin Y, Zhang H, Jia Z, et al. Resveratrol improves uric acid-induced pancreatic beta-cells injury and dysfunction through regulation of miR-126. Biomed Pharmacother 2018; 102: 1120-6.
 
37.
Hou Z, Wang Z, Tao Y, et al. KLF2 regulates osteoblast differentiation by targeting of Runx2. Lab Invest 2019; 99: 271-80.
 
38.
Wu JC, Sun J, Xu JC, Zhou ZY, Zhang YF. Down-regulated microRNA-199a-3p enhances osteogenic differentiation of bone marrow mesenchymal stem cells by targeting Kdm3a in ovariectomized rats. Biochem J 2021; 478: 721-34.
 
39.
Wang D, Zhang Y, Xu X, et al. YAP promotes the activation of NLRP3 inflammasome via blocking K27-linked polyubiquitination of NLRP3. Nat Commun 2021; 12: 2674.
 
40.
He Q, Qin R, Glowacki J, et al. Synergistic stimulation of osteoblast differentiation of rat mesenchymal stem cells by leptin and 25(OH)D(3) is mediated by inhibition of chaperone-mediated autophagy. Stem Cell Res Ther 2021; 12: 557.
 
41.
Zheng HL, Xu WN, Zhou WS, et al. Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination. Cell Death Dis 2021; 12: 497.
 
42.
Kong Y, Nie ZK, Li F, Guo HM, Yang XL, Ding SF. MiR-320a was highly expressed in postmenopausal osteoporosis and acts as a negative regulator in MC3T3E1 cells by reducing MAP9 and inhibiting PI3K/AKT signaling pathway. Exp Mol Pathol 2019; 110: 104282.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top